Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.47 |
| ▸ | RET | P07949 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | ROS1 | P08922 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572199 | 0.87 | SRC (0.54) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL4572200 | 0.87 | SRC (0.54) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL4572197 | 0.87 | SRC (0.54) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL27604421 | 0.86 | RET (0.40) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL3832435 | 0.85 | ADK (0.49) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL4572203 | 0.84 | SRC (0.44) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL868687 | 0.83 | ABL1 (0.58) | SRCRETKDRABL1HCK | |
| SCHEMBL20263231 | 0.82 | RET (0.42) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL30104023 | 0.79 | SRC (0.48) | SRCRETKDRDYRK3CDK1 | |
| SCHEMBL29588925 | 0.77 | RET (0.59) | SRCRETKDRLCKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SRC 241/4885RET 652/4885KDR 1642/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | SRC 188/4885RET 341/4885KDR 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.